FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3099708384> ?p ?o ?g. }

• W3099708384 endingPage "e23053" @default.
• W3099708384 startingPage "e23053" @default.
• W3099708384 abstract "The human epidermal growth factor receptor 2 (HER2) is amplified in approximately 20% of breast cancers, and HER2 receptor targeting therapy is associated with a significant improvement in disease-free and overall survival. In several clinical trials, the pathologic complete response (pCR) rate was significantly increased with combined pertuzumab and trastuzumab treatment in HER2-amplified breast cancer. Although the efficacy and safety of anti-HER2 dual blockade therapy has been reported, the markers that predict the response are still unclear. This study aimed to investigate the relationship between the level of HER2 amplification and the pCR in trastuzumab and pertuzumab neoadjuvant therapy.Twenty-two HER2-amplified early breast cancer patients who had received neoadjuvant docetaxel, carboplatin, trastuzumab, and pertuzumab (TCHP) therapy were included in this study. HER2/CEP17 ratio and average HER2 copy number were measured by fluorescence in situ hybridization analysis. The relationship between level of HER2 amplification and tumor pCR status was investigated.The median age was 47.5 years (range, 36-62). 31.8% of the patients were hormone receptor (HR) positive and 68.2%% of the patients were HR negative. The pCR (ypN0/is ypN0) rate in the breast and axilla was 68.2%. The patients who experienced a pCR had a median HER2/CEP17 ratio of 7.08 (range, 3.16-10.40) and average HER2 copy number of 17.00 (range, 5.85-37.50). The patients who did not experience a pCR had a median ratio of 4.70 (range, 1.06-9.00) and median HER2 copy number of 12.00 (range, 5.85-20.95) (P = .030, P = .174), respectively.pCR was highly correlated with HER2/CEP17 ratio in neoadjuvant anti-HER2 dual blockade. This suggests that the HER2/CEP17 ratio can be used as a predictive marker for pCR in neoadjuvant trastuzumab and pertuzumab therapy." @default.
• W3099708384 created "2020-11-23" @default.
• W3099708384 creator A5006554886 @default.
• W3099708384 creator A5014151447 @default.
• W3099708384 creator A5017048064 @default.
• W3099708384 creator A5074980266 @default.
• W3099708384 date "2020-11-13" @default.
• W3099708384 modified "2023-09-26" @default.
• W3099708384 title "Pathological complete response to neoadjuvant trastuzumab and pertuzumab therapy is related to human epidermal growth factor receptor 2 (HER2) amplification level in HER2-amplified breast cancer" @default.
• W3099708384 cites W1867197625 @default.
• W3099708384 cites W1892496998 @default.
• W3099708384 cites W1987326983 @default.
• W3099708384 cites W2040935952 @default.
• W3099708384 cites W2044791827 @default.
• W3099708384 cites W2046637765 @default.
• W3099708384 cites W2078881615 @default.
• W3099708384 cites W2080661875 @default.
• W3099708384 cites W2095861620 @default.
• W3099708384 cites W2095865154 @default.
• W3099708384 cites W2101979288 @default.
• W3099708384 cites W2103939496 @default.
• W3099708384 cites W2104337757 @default.
• W3099708384 cites W2111578514 @default.
• W3099708384 cites W2123591186 @default.
• W3099708384 cites W2141393790 @default.
• W3099708384 cites W2144124503 @default.
• W3099708384 cites W2146384083 @default.
• W3099708384 cites W2149773268 @default.
• W3099708384 cites W2149908785 @default.
• W3099708384 cites W2151262170 @default.
• W3099708384 cites W2159967578 @default.
• W3099708384 cites W2165249233 @default.
• W3099708384 cites W2166199281 @default.
• W3099708384 cites W2318605753 @default.
• W3099708384 cites W2379981061 @default.
• W3099708384 cites W2585180563 @default.
• W3099708384 cites W2624590002 @default.
• W3099708384 cites W2768649895 @default.
• W3099708384 doi "https://doi.org/10.1097/md.0000000000023053" @default.
• W3099708384 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7668516" @default.
• W3099708384 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33181670" @default.
• W3099708384 hasPublicationYear "2020" @default.
• W3099708384 type Work @default.
• W3099708384 sameAs 3099708384 @default.
• W3099708384 citedByCount "8" @default.
• W3099708384 countsByYear W30997083842021 @default.
• W3099708384 countsByYear W30997083842022 @default.
• W3099708384 countsByYear W30997083842023 @default.
• W3099708384 crossrefType "journal-article" @default.
• W3099708384 hasAuthorship W3099708384A5006554886 @default.
• W3099708384 hasAuthorship W3099708384A5014151447 @default.
• W3099708384 hasAuthorship W3099708384A5017048064 @default.
• W3099708384 hasAuthorship W3099708384A5074980266 @default.
• W3099708384 hasBestOaLocation W30997083841 @default.
• W3099708384 hasConcept C121608353 @default.
• W3099708384 hasConcept C126322002 @default.
• W3099708384 hasConcept C143998085 @default.
• W3099708384 hasConcept C2777329042 @default.
• W3099708384 hasConcept C2778292576 @default.
• W3099708384 hasConcept C2779786085 @default.
• W3099708384 hasConcept C2781164504 @default.
• W3099708384 hasConcept C2781190966 @default.
• W3099708384 hasConcept C530470458 @default.
• W3099708384 hasConcept C71924100 @default.
• W3099708384 hasConceptScore W3099708384C121608353 @default.
• W3099708384 hasConceptScore W3099708384C126322002 @default.
• W3099708384 hasConceptScore W3099708384C143998085 @default.
• W3099708384 hasConceptScore W3099708384C2777329042 @default.
• W3099708384 hasConceptScore W3099708384C2778292576 @default.
• W3099708384 hasConceptScore W3099708384C2779786085 @default.
• W3099708384 hasConceptScore W3099708384C2781164504 @default.
• W3099708384 hasConceptScore W3099708384C2781190966 @default.
• W3099708384 hasConceptScore W3099708384C530470458 @default.
• W3099708384 hasConceptScore W3099708384C71924100 @default.
• W3099708384 hasFunder F4320322120 @default.
• W3099708384 hasIssue "46" @default.
• W3099708384 hasLocation W30997083841 @default.
• W3099708384 hasLocation W30997083842 @default.
• W3099708384 hasLocation W30997083843 @default.
• W3099708384 hasOpenAccess W3099708384 @default.
• W3099708384 hasPrimaryLocation W30997083841 @default.
• W3099708384 hasRelatedWork W2010059199 @default.
• W3099708384 hasRelatedWork W2061349734 @default.
• W3099708384 hasRelatedWork W228818084 @default.
• W3099708384 hasRelatedWork W2588830645 @default.
• W3099708384 hasRelatedWork W2593886517 @default.
• W3099708384 hasRelatedWork W2901487801 @default.
• W3099708384 hasRelatedWork W2998878522 @default.
• W3099708384 hasRelatedWork W3000605535 @default.
• W3099708384 hasRelatedWork W3026789962 @default.
• W3099708384 hasRelatedWork W4242374293 @default.
• W3099708384 hasVolume "99" @default.
• W3099708384 isParatext "false" @default.
• W3099708384 isRetracted "false" @default.
• W3099708384 magId "3099708384" @default.
• W3099708384 workType "article" @default.